secwatch.observer — SEC 8-K summary
======================================

Issuer:     KYNTRA BIO, INC. (KYNB)
CIK:        0000921299
Form:       8-K
Filed at:   2024-06-07T23:59:59+00:00
Accession:  0000950170-24-070636
Event type: other_material
Sentiment:  neutral
Materiality: 0.15
Item codes: 5.07, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

FibroGen stockholders approve 2024 Equity Incentive Plan and elect directors
----------------------------------------------------------------------------

- Class I directors elected: Thane Wettig (54.9M for), James Schoeneck (53.1M for), Maykin Ho (53.6M for).
- 2024 Equity Incentive Plan approved: 44.3M for, 10.8M against; plan adds 2.2M new shares plus prior plan reserve.
- Advisory vote on executive compensation approved: 53.5M for, 1.75M against.
- PricewaterhouseCoopers ratified as independent auditor for 2024: 72.5M for, 0.2M against.
- Say-on-pay frequency: every year preferred (54.8M votes).

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/921299/000095017024070636/0000950170-24-070636-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/921299/000095017024070636/fgen-20240605.htm
  HTML page:      https://secwatch.observer/filing/0000950170-24-070636

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer